GSK Says Will 'Sit Out' Current Big M&A Frenzy
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline PLC says it will not join the current melee of big M&A sweeping the sector but will instead concentrate on 'bedding down' its constituent parts after its transformational asset swap with Swiss rival Novartis AG, completed last year.